Biotechnology

Biomea Fusion

Biomea Fusion expects to complete the food effect study for icovamenib by December 2025

Biomea Fusion plans to initiate two new Phase II clinical trials in Q4 2025

Biomea Fusion presented positive preclinical data at the ObesityWeek® 2025 conference

D. Boral Capital Maintains Buy Rating on Biomea Fusion, but Lowers Price Target to $12

Biomea Fusion expects to initiate two key Phase II clinical trials in Q4 2025

Biomea Fusion expected to complete Food Effect Study (COVALENT-121) for icovamenib

D. Boral Capital Maintains Buy Rating on Biomea Fusion, Lowers Price Target to $12

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Biomea Fusion expects to report initial data for its oral GLP-1 drug, BMF-650, in the first half of 2026

Biomea Fusion is expected to initiate a Phase IIb clinical trial for icovamenib in the fourth quarter of 2025

JPMorgan downgrades Biomea Fusion to Underweight from Neutral

Phase IIb Trial COVALENT-211 Planned for Initiation in Q4 2025

D. Boral Capital maintains Buy rating on Biomea Fusion, but lowers price target to $12

Citigroup Lowers Biomea Fusion Price Target but Maintains 'Buy' Rating

Biomea Fusion Announces Participation at Jefferies London Healthcare Conference

Biomea Fusion presented positive preclinical data for drug candidates at ObesityWeek® 2025.

Biomea Fusion anticipates releasing weight reduction data for its oral GLP-1 candidate BMF-650 in the first half of 2026

Biomea Fusion plans to initiate two key Phase II clinical trials in the fourth quarter of 2025

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

Foxx Development

Palatin Tech

Mobile-Health Network Solutions

Nuvve

Datavault AI

CCSC Tech

Iveda Solutions

Harrison Global

Alps

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap